Angiogenesis Inhibition

Angiogenesis is attracting increased scientific and clinical interest. The identification of novel mediators and targeting molecules has led to significant progress in our understanding of tumor angiogenesis and tumor vessel targeting. Important advances in cancer treatment have already emerged, and in the future, blood vessel targeting will play a significant role within individualized therapeutic strategies. This volume provides a general overview of the latest developments in angiogenesis inhibition in cancer. All aspects from the bench to the bedside are considered, with detailed attention both to basic research and to its translation into clinical practice. Individual chapters are devoted to the roles of angiopoietins, HIF-1a, chemokines, PDGF and VEGF, and vascular integrins. The latest results of clinical trials are presented, and various advanced targeting strategies are discussed. This book will be invaluable to all who wish to learn of the most recent advances in this exciting field.

Angiogenesis -- the growth of new blood vessels -- is an important natural process occurring in the body, both for health and as related to disease. Angiogenesis occurs in the healthy body to help heal wounds and to help to restore blood flow to tissues after injury or insult. In females, Angiogenesis also occurs during the monthly reproductive cycle (to rebuild the uterus lining, to mature the egg during ovulation) and during pregnancy (to build the placenta, the circulation between mother and foetus). The healthy body controls angiogenesis through a series of "on" and "off" switches. The main "on" switches are known as angiogenesis-stimulating growth factors. The main "off switches" are known as angiogenesis inhibitors. When angiogenic growth factors are produced in excess of angiogenesis inhibitors the balance is tipped in favour of blood vessel growth. When inhibitors are present in excess of stimulators, angiogenesis is stopped. The normal, healthy body maintains a perfect balance of angiogenesis modulators. In general, angiogenesis is "turned off" by the production of more inhibitors than stimulators. Tumour angiogenesis is the proliferation of a network of blood vessels that penetrates into cancerous growths, supplying nutrients and oxygen and removing waste products. Tumour angiogenesis actually starts with cancerous tumour cells releasing molecules that send signals to surrounding normal host tissue. This signalling activates certain genes in the host tissue that, in turn, cause proteins to encourage growth of new blood vessels. This book examines its angiogenesis within the context of theory and its applications to cancer treatment.

Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches. Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences. Covers important preclinical models and clinical trials in the discovery and development of novel anti-angiogenesis agents Reviews FDA-approved anti-angiogenesis agents Illustrates the value of nanotechnology in improving the utility of anti-angiogenesis agents Offers insight into the development of novel anti-angiogenesis agents and future direction in this area

Dr. Judah Folkman is considered the "father of angiogenesis." Because of Folkman's discovery and research, the possibilities of angiogenic therapy have broadened beyond cancer to many noncancerous diseases. Angiogenesis: An Integrative Approach from Science to Medicine is a comprehensive, concise summary of tumor angiogenesis. It is an up-to-date and authoritative reference for the angiogenesis field as it relates to oncology. This book represents the first collection in a volume of which Folkman is co-editor. Folkman has authored nearly 400 original papers and more than 100 book chapters.

The regulation of blood vessel growth underlies many normal biological processes such as reproduction, development, repair and wound healing. It also is a critical feature of pathological processes such as cancer, diabetic retinopathy, macular degeneration, inflammatory arthritis and ischemic heart disease. What causes blood vessels to grow? What inhibits their growth? This book comprehensively describes the angiogenic proteins that enhance and inhibit normal and abnormal angiogenesis. It describes the potential therapeutic applications of basic fibroblast growth factor, vascular endothelial growth factor, PECAM-1 and thrombospondin as well as other factors. The book brings together information about new blood vessel formation in many organ systems and comprises an outstanding resource on the state-of-the art in angiogenesis.

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, and wound healing disorders. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Anti-angiogenesis Drug Discovery and Development provides an excellent compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. The feast of these reader-friendly reviews on topics of great scientific importance – many of which are considered significant medical breakthroughs, makes this series excellent reading both for the novice as well as for expert medicinal chemists and clinicians. The fifth volume brings together reviews on the following topics: - Targeted therapy for tumor vasculature - Anti-angiogenic therapy for breast and prostate cancers (including information updates on clinical trials) - Microbe-based and other novel antiangiogenesis therapies such as chromene-based agents

Tumor angiogenesis is one of the most prominent mechanisms driving tumor development and progression. This book is written by internationally renowned experts. Part 1 describes the basic mechanisms. Tumor-angiogenic signaling pathways are presented as new potential targets for anti-angiogenic therapy. Part 2 reviews the efforts made to validate new targets and to show efficacy in animals. Part 3 is devoted to the clinical development of the novel anti-angiogenic drugs and their use in clinical practice.

This volume addresses current emerging concepts in the field of angiogenesis, including important angiogenesis modifiers which are essential in combination with growth factors (VEGF and FGF) for the physiological process and also for therapeutic applications. It covers many of the lesser discussed areas including blood vessel growth guidance (interactions with CNS) as well as emerging practical applications of these concepts. The book comprises in-depth reviews by leading experts in several major areas: recent basic science discoveries about angiogenesis modifiers (semaphorins, ephrins and nitric oxide, for which the Nobel Prize was awarded); arterial guidance; clinical applications of new angiogenic factors (HGF, HIF and eNOS); and basic and clinical advancement of anti-angiogenic molecules for the treatment of cancer and macular degeneration (tyrosine kinase inhibitors and NO). These topics, especially their unique combination presented in this volume, are not found in any other current books on angiogenesis. This makes the book a must-read for readers both interested and actively involved in the most recent advances in basic principles and clinical applications of angiogenesis. Contents:Semaphorins, Plexins and Neuropilins and Their Role in Vasculogenesis and Angiogenesis (G Neufeld et al.)EPH Receptors and Ephrins (E B Pasquale)The FGF Family of Angiogenic Growth Factors (P Auguste & A Bikfalvi)Neuropeptide Y: Neurogenic Mediator of Angiogenesis and Arteriogenesis (J B Kitlinska & Z Zukowska)Modulation of Growth Factor Signaling by Heparan Sulfate Proteoglycans (N W Shworak)Directional Cues in Angiogenesis (A Horowitz)Regulation of Angiogenesis and Arteriogenesis by Hypoxia-Inducible Factor 1 (G L Semenza)Redox State and Regulation of Angiogenic Responses (M Ushio-Fukai & R W Alexander)Angiogenesis and Arteriogenesis in Cardiac Hypertrophy (R J Tomanek & E I Dedkov)Regulation of Coronary Vascular Tone and Microvascular Physiology (B Ramlawi et al.)Kinase Inhibitors: Cancer Drugs Derived from Mechanistic Considerations (K-H Thierauch & A Chlistalla)Therapeutic Angiogenesis — An Overview (M Murakami & M Simons)Hepatocyte Growth Factor (R Morishita & T Ogihara)Role of Nitric Oxide in Adult Angiogenesis: Therapeutic Potential of Endothelial Nitric Oxide Synthase Gene Transfer (G M Rubanyi) Readership: Vascular biologists; trainees in vascular biology, cardiology and cancer medicine; clinicians interested in basic science of angiogenesis; industrial scientists; biotechnology companies. Keywords:Arteriogenesis;Angiogenesis;Arterial Guidance;Clinical Trials;Endothelial Cells;Regulation of Signaling;Nitric Oxide;Periferal Vascular Disease;Myocardial Ischemia;Therapeutic Angiogenesis;RevascularizationKey Features:Contains a detailed discussion of arterial guidanceCovers angiogenesis modifiers not discussed in-depth in any other book (semaphorins and nitric oxide synthase)Includes the most recent clinical advances in therapeutic angiogenesis (HGF and HIF)Deals with basic and clinical aspects of anti-angiogenic therapy for cancerDiscusses translational applicationsWritten by leading experts on the most recent emerging topics